# BV-AVD-R Treatment Children Hodgkin's Lymphoma

> **NCT06201507** · PHASE2 · UNKNOWN · sponsor: **Beijing Children's Hospital** · enrollment: 44 (estimated)

## Conditions studied

- Hodgkin Lymphoma

## Interventions

- **DRUG:** Brentuximab vedotin
- **DRUG:** Rituximab
- **DRUG:** Doxorubicin
- **DRUG:** Vincristine
- **DRUG:** Dacarbazine

## Key facts

- **NCT ID:** NCT06201507
- **Lead sponsor:** Beijing Children's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-10-01
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2024-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06201507

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06201507, "BV-AVD-R Treatment Children Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06201507. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*